What Has Been the Growth of the Biobetters Market So Far?
The biobetters market has seen considerable growth due to a variety of factors.
• The biobetters market has grown rapidly in recent years. It is projected to rise from $67.81 billion in 2024 to $75.98 billion in 2025, at a CAGR of 12.0%.
Contributing factors include better understanding of disease mechanisms, rising healthcare spending, improvements in manufacturing technologies, innovations in drug delivery, advancements in protein engineering, and greater demand for more effective therapies.
What Is the Forecasted Market Size and Growth Rate for The Biobetters Market Size In The Coming Years?
The biobetters market is expected to maintain its strong growth trajectory in upcoming years.
• The biobetters market is forecast to grow rapidly, reaching $118.2 billion by 2029, at a CAGR of 11.7%.
The growth is attributed to advancements in biotechnology, a stronger focus on personalized medicine, expanding biopharma pipelines, increasing chronic disease prevalence, favorable regulatory environments, and heightened investment in R&D. Trends include the development of novel biobetters, protein engineering, focus on therapeutic areas, advanced healthcare infrastructure, next-generation sequencing (NGS), and high-throughput screening (HTS) technologies.
What Factors Are Driving Growth In The Biobetters Market?
The growing incidence of chronic kidney diseases is projected to drive the growth of the biobetters market. Chronic kidney disease (CKD) affects the kidneys, causing them to lose their function over time. With an aging population, rising rates of diabetes, hypertension, poor eating habits, and increased diagnostic capabilities, CKD is becoming more prevalent. Biobetters offer improved treatments for CKD by enhancing efficacy, minimizing side effects, and providing better dosing regimens. For example, CKD prevalence in the UK is expected to rise from 8.27 million to 8.61 million between 2022 and 2032, driving demand for biobetters.
What Are The Main Segments Of The Global Biobetters Market?
The biobetters market covered in this report is segmented –
1) By Drug Class: Erythropoietin Biobetters, Granulocyte-Colony Stimulating Factor (G-CSF) Bioreactors, Interferon Biobetters, Insulin Biobetters, Monoclonal Antibodies Biobetters, Antihemophilic Factors, Other Drug Classes
2) By Route Of Administration: Oral, Subcutaneous, Inhaled, Intravenous, Other Routes
3) By Disease Indication: Diabetes, Cancer, Renal Disease, Neurodegenerative Diseases, Genetic Disorder-Hemophilia, Other Diseases
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Erythropoietin Biobetters: Darbepoetin Alfa, Continuous Erythropoietin Receptor Activator (CERA)
2) By Granulocyte-Colony Stimulating Factor (G-CSF) Biobetters: Pegfilgrastim, Lipegfilgrastim
3) By Interferon Biobetters: Pegylated Interferon Alfa-2a, Pegylated Interferon Alfa-2b
4) By Insulin Biobetters: Long-Acting Insulin Analogs (Insulin Glargine), Rapid-Acting Insulin Analogs (Insulin Aspart)
5) By Monoclonal Antibodies Biobetters: Trastuzumab (Herceptin Biosimilars), Bevacizumab (Avastin Biosimilars), Rituximab (Rituxan Biosimilars)
6) By Antihemophilic Factors: Recombinant Factor VIII (Nuwiq), Recombinant Factor IX (Alprolix)
7) By Other Drug Classes: Growth Factors, Cytokines, Enzyme Replacement Therapies, Vaccines
Pre-Book The Biobetters Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Biobetters Market?
Leading companies in the biobetters market are focusing on developing biobetters for subcutaneous administration to enhance patient convenience, improve treatment outcomes, and reduce healthcare expenses. Subcutaneous administration presents a more convenient alternative to intravenous infusion, potentially increasing patient adherence and making healthcare delivery more efficient. For example, in May 2023, South Korea's Celltrion received approval from the Brazilian Health Regulatory Agency for Remsima SC biobetters, an advanced version of their infliximab biosimilar, Remsima. Remsima SC is the only infliximab product worldwide offering subcutaneous administration, improving accessibility and effectiveness for treating conditions like Crohn's disease and ulcerative colitis.
Who Are the Key Players In The Biobetters Market?
Major companies operating in the biobetters market are:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co Inc.
• AbbVie Inc.
• Bayer AG
• Sanofi Aventis LLC
• Bristol-Myers Squibb Company
• Novartis AG
• GlaxoSmithKline plc
• F Hoffmann La Roche Ltd.
• Eli Lilly and Co Ltd.
• Gilead Sciences Inc.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• CSL Behring GmbH
• Biogen Inc.
• GRIFOLS USA LLC
• Celltrion Inc.
• Lonza Group AG
• Ionis Pharmaceuticals Inc.Incyte Corporation
• Amicus Therapeutics Inc.
• Genentech Inc.
• Sun Pharmaceutical Industries
What Is The Most Dominant Region In The Biobetters Market?
North America was the largest region in the biobetters market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biobetters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
